Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Poteligeo Now Indicated for Chemotherapy-Naïve CCR4-Positive ATL: Kyowa Kirin
December 19, 2014
- Taiho’s Abraxane Gets Nod for Unresectable Pancreatic Cancer
December 19, 2014
- Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
- MTPC Reorganizing Its US Affiliates to Accelerate Operation Expansion
December 19, 2014
- Fujifilm Holdings Makes J-TEC Its Consolidated Subsidiary
December 19, 2014
- Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs
December 18, 2014
- CRO Intellim to Collaborate with Indian Firm for CDISC
December 18, 2014
- Novartis Confirms Additional Cases of Employee Involvement in IIT, but Denies Falsification or Manipulation of Data
December 18, 2014
- Ribomic to Extend Joint Research Term by 1 Year with Otsuka for Hematological Disorder, Fibrosis Projects
December 18, 2014
- Chugai to File for Approval of Xeloda as Gastric Cancer Adjuvant Therapy by Year-End
December 17, 2014
- Xtandi Demonstrates Clinical Benefit for Advanced Breast Cancer in PII Study: Astellas
December 17, 2014
- Battle Begins for Blopress Generics
December 16, 2014
- Eliquis the First NOAC with Safety Information Announced for Over 100,000 Patients
December 16, 2014
- Kaketsuken, Teijin Pharma Initiate Voluntary Recall of Venilon after Wool Fiber Found in Vial of Dissolved Product
December 16, 2014
- Otsuka Initiates Tender Offer to Acquire All Outstanding Shares of Avanir for US$17 per Share
December 16, 2014
- ViiV Healthcare Files NDA for Triple-Combination HIV Agent in Japan
December 16, 2014
- With Mandatory CDISC-Based Submission Looming, CRO A2 Sees Soaring Orders from Japanese Drug Makers
December 16, 2014
- Sanofi Reiterates Alert on Proper Use of Jevtana; Five Deaths Reported Since Launch in September
December 15, 2014
- Sumitomo Dainippon Aims for NDA Filing for ADHD Treatment Dasotraline in FY2017 in US
December 15, 2014
- Kyowa Kirin Aims to Score Global Sales of 20 Billion Yen for Poteligeo in a Few Years: President Hanai
December 15, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…